Latest News
PDMR dealings
03 June 2019
New York/London, 3 June 2019 – Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, announces that on 31 May 2019, Panetta Partners...
Results of Annual General Meeting
31 May 2019
Tiziana announces that at the Annual General Meeting of the Company held at 10:00 a.m. on 31 May 2019 all the resolutions proposed were duly passed.
Tiziana Life Sciences to Present at the 9th Annual LD Micro Invitational
28 May 2019
New York / London May 28, 2018 Tiziana Life Sciences plc (Nasdaq: TLSA / AIM: TILS), a biotechnology company focusing on the discovery and development of innovative therapeutics for inflammation and oncology indications, today announced that it will...
Notice of Annual General Meeting
07 May 2019
Tiziana Life Sciences plc announces that its Annual General Meeting will be held at 10:00 a.m. on Friday 31 May 2019 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.
PDMR dealings
02 May 2019
Tiziana announces that on 1 May 2019, Panetta Partners Limited, an entity closely associated with Gabriele Cerrone, Executive Chairman, bought ordinary shares of nominal value 3p each in the capital of the Company, as set out below, following prior consultation with the Takeover Panel in relation to Note 11 to Rule 9.1 of the City Code on Takeovers and Mergers.
Update on IND Application for Oral Formulation of Foralumab for Treatment of NASH
01 May 2019
Tiziana announces an update regarding its Investigational New Drug application to the FDA to initiate a Phase 1 clinical trial of enteric-coated capsules of Foralumab in healthy volunteers.